The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations

Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.

The stock that made headlines during the week was Amarin Corporation plc AMRN, which slumped on an adverse court ruling.

The following are catalysts that could impact biotech stocks in the unfolding week.

The focus is likely to stay on pre-clinical and clinical updates from companies developing therapies and/or vaccines for SARS-CoV-2. More companies are expected to update investors with preliminary first-quarter results that factor in the COVID-19 impact.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Conferences

• Goldman Sachs Cell Therapy Day: April 6
• 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 7 in Boston, Massachusetts
• Canaccord Genuity Horizons in Oncology Virtual Event: April 8 in Boston 
• 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 9 in San Francisco, California

Clinical Readouts

Menlo Therapeutics Inc MNLO: top-line data from two ongoing serlopitant Phase 3 studies in pruritus associated with prurigo nodularis (late March/early April)

Oragenics Inc OGEN: Results from the Phase 2 study of AG013 in oral mucositis (early 2020)

Earnings

• AngioDynamics, Inc. ANGO (Tuesday after the close)
• PAVmed Inc PAVM (Thursday after the close)

IPOs

Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, plans to offer 5 million shares in an IPO priced between $14 and $16. The company has applied to list its shares on the Nasdaq under the ticker symbol "KROS."

IPO Quiet Period Expiry

Imara Inc IMRA

Related Links:

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

10 Biotech Winners And Losers In Q1